30 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
27 Feb 24
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
7:04am
up to $275 million of milestone payments and mid-to-high single-digit royalties.
Hosted a webcast with gynecologic oncology academic expert
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
9 Aug 23
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
7:03am
Funda Meric-Bernstam, M.D., a widely recognized Phase 1 trial expert and experimental therapeutics researcher in oncology, to its Scientific Advisory
8-K
EX-99.1
82sk673 7x
10 May 23
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
7:04am
PRE 14A
36wipkb
18 Apr 23
Preliminary proxy
4:30pm
8-K
EX-99.2
xckt76cezl4r7y4i9s
9 Aug 22
Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update
12:00am
8-K
EX-99.1
u1m ssvl2ft
8 Apr 22
Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR
5:05pm
DEF 14A
egpyw7 64nzeggoxb2h
23 Apr 21
Definitive proxy
4:05pm
8-K
EX-10.1
pbwn2 b5u35q4
2 Oct 20
Entry into a Material Definitive Agreement
4:51pm
424B4
bwbqkn
31 Jul 20
Prospectus supplement with pricing info
12:00am
DRS
EX-10.21
4z50sgvqv bcwhqdvv2
10 Jul 20
Draft registration statement
12:00am
DRS
EX-10.6
cegumri1lsbawx dzj
10 Jul 20
Draft registration statement
12:00am